Thijs Abel, Grooteman Muriel P C, Zweegman Sonja, Nubé Menso J, Huijgens Peter C, Stehouwer Coen D A
Department of Internal Medicine, VU University Medical Centre, Amsterdam, The Netherlands.
Blood Purif. 2007;25(5-6):389-94. doi: 10.1159/000108628. Epub 2007 Sep 20.
BACKGROUND/AIM: Haemodialysis-treated patients are at a high risk of developing cardiovascular disease. Part of this risk may be attributable to the type of the dialysis membrane used. We evaluated whether different dialysis membranes differ with respect to platelet activation.
In a randomized crossover trial, the platelet activation was measured in 14 patients treated with two different dialyzers (cuprammonium rayon membrane and polysulfone membrane). We compared the platelet activation over the dialyzer and between dialyzers after several weeks of dialysis.
There were no differences between the two dialyzers in platelet activation over the dialyzer. After 2 weeks, however, the expression of CD62P, CD63, and PAC-1 was statistically significantly lower after cuprammonium membrane treatment than after polysulfone membrane treatment (mean fluorescence intensity in arbitrary units 8.0 vs. 11.1, 2.64 vs. 4.01, and 5.61 vs. 9.74, respectively).
Dialysis with a polysulfone membrane seems to lead to more platelet activation than dialysis with a cuprammonium membrane.
背景/目的：接受血液透析治疗的患者患心血管疾病的风险很高。这种风险的一部分可能归因于所使用的透析膜类型。我们评估了不同的透析膜在血小板活化方面是否存在差异。
在一项随机交叉试验中，对14名使用两种不同透析器（铜氨人造丝膜和聚砜膜）进行治疗的患者的血小板活化情况进行了测量。我们比较了透析数周后透析器内以及不同透析器之间的血小板活化情况。
两种透析器在透析器内的血小板活化情况没有差异。然而，2周后，铜氨膜治疗后的CD62P、CD63和PAC-1表达在统计学上显著低于聚砜膜治疗后（平均荧光强度分别为任意单位8.0对11.1、2.64对4.01和5.61对9.74）。
与使用铜氨膜透析相比，使用聚砜膜透析似乎会导致更多的血小板活化。
